Leying Jiang

1 Introduction Vaccines are effective tools for preventing respiratory diseases, and their role in tumor immunotherapy has gradually become prominent.[1] Subunit vaccines and split vaccines, to some extent, avoided the safety issues of whole-pathogen vaccines and hold great potential in clinical application.[2] While non-adjuvanted subunit vaccines can only lead to limited immune efficacy.[3] Adjuvant, usually as a constituent, was added to vaccines to enhance the immune intensity and...

1 Introduction The mRNA vaccine encoding 34 neoantigens in phase IIb clinical trial has ushered the main end in 2022, heralding the great promise of neoantigens as personalized vaccines for tumor treatment.[1] Meanwhile, as the first approved personalized tumor vaccine for clinical trials, the progress of peptide-based neoantigens has lagged behind the mRNA vaccines, which can be owed to the rapid metabolism, inefficient delivery to draining lymph nodes, and low immunogenicity of peptides.[2]...

Abstract Ultrasensitive identification of biomarkers in biofluids is essential for precise diagnosis of diseases. For the gold standard approaches, polymerase chain reaction and enzyme-linked immunosorbent assay, cumbersome operational steps hinder their point-of-care applications. Here, w e implement a bionic biomarker entrapment system (BioES), which employs a multi-body Y-shaped tetrahedral DNA probe immobilized on carbon nanotube transistors.